William Chey and colleagues performed a meta-analysis and systematic review of five randomized, placebo-controlled trials to determine the efficacy and tolerability of the minimally absorbed antibiotic rifaximin in patients with IBS. Rifaximin was more effective than placebo for global IBS symptom improvement and bloating. Adverse effects were similar among patients in the two groups.
ORIGINAL RESEARCH PAPER
Menees, S. B. et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am. J. Gastroenterol. doi:10.1038/ajg.2011.355
Rights and permissions
About this article
Cite this article
Rifamixin for the treatment of IBS. Nat Rev Gastroenterol Hepatol 9, 6 (2012). https://doi.org/10.1038/nrgastro.2011.233
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.233